{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:11:26Z","timestamp":1761808286529,"version":"3.40.5"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus. Patients with stable coronary disease and diabetes are also at elevated risk and might benefit from dual antiplatelet therapy. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b randomized, double\u2010blinded, placebo\u2010controlled trial of ticagrelor vs placebo, on top of low dose aspirin. Patients \u226550\u2009years with type 2 diabetes receiving anti\u2010diabetic medications for at least 6 months with stable coronary artery disease as determined by a history of previous percutaneous coronary intervention, bypass grafting, or angiographic stenosis of \u226550% of at least one coronary artery were enrolled. Patients with known prior myocardial infarction (MI) or stroke were excluded. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding. A total of 19\u2009220 patients worldwide have been randomized and at least 1385 adjudicated primary efficacy endpoint events are expected to be available for analysis, with an expected average follow\u2010up of 40\u2009months (maximum 58\u2009months). Most of the exposure is on a 60\u2009mg twice daily dose, as the dose was lowered from 90\u2009mg twice daily partway into the study. The results may revise the boundaries of efficacy for dual antiplatelet therapy and whether it has a role outside acute coronary syndromes, prior myocardial infarction, or percutaneous coronary intervention.<\/jats:p>","DOI":"10.1002\/clc.23164","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T03:39:46Z","timestamp":1550720386000},"page":"498-505","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Fox","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College and Royal Brompton Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University  Stanford California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St. Michael's Hospital University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Population Health Research Institute Hamilton Health Sciences and McMaster University  Hamilton Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tabassome","family":"Simon","sequence":"additional","affiliation":[{"name":"AP\u2010HP, H\u00f4pital Saint Antoine, Department of Clinical Pharmacology\u2010URCEST Sorbonne\u2010Universit\u00e9 Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marielle","family":"Andersson","sequence":"additional","affiliation":[{"name":"AstraZeneca Gothenburg, Department of Cardiovascular, Renal and Metabolism  M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Himmelmann","sequence":"additional","affiliation":[{"name":"AstraZeneca Gothenburg, Department of Cardiovascular, Renal and Metabolism  M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Ridderstr\u00e5le","sequence":"additional","affiliation":[{"name":"AstraZeneca Gothenburg, Department of Cardiovascular, Renal and Metabolism  M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"FACT (French Alliance for Cardiovascular Trials), an F\u2010CRIN Network, D\u00e9partement Hospitalo\u2010Universitaire FIRE, AP\u2010HP, H\u00f4pital Bichat Universit\u00e9 Paris\u2010Diderot  Paris France"},{"name":"D\u00e9partement Hospitalo\u2010Universitaire FIRE, AP\u2010HP, H\u00f4pital Bichat,Universit\u00e9 Paris\u2010Diderot, INSERM U\u20101148  Paris France"},{"name":"National Heart &amp; Lung Institute NHLI, Imperial College, Royal Brompton Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the THEMIS Steering Committee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014796"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200112063452321"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205512"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61451-8"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62191-7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.927582"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002589"},{"issue":"4","key":"e_1_2_8_12_1","first-page":"390","article-title":"Long\u2010term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta\u2010analysis of randomized trials","volume":"37","author":"Udell JA","year":"2016","journal-title":"Eur Heart J"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.03.025"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.529"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.524"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32409-1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025880"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603060"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31858-0"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31884-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.09.006"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.913376"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.06.008"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.050"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803955"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804988"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31924-X"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.038"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2430"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.06.1170"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.08.014"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02567-5"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq325"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.791061"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023402"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.12.062"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-09-0703"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.23164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clc.23164","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T06:59:57Z","timestamp":1693983597000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.23164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/clc.23164"],"URL":"https:\/\/doi.org\/10.1002\/clc.23164","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"type":"print","value":"0160-9289"},{"type":"electronic","value":"1932-8737"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"2019-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}